Skip to main content Skip to search Skip to main navigation

Swissmedic: Invalid Certification of the Notified Body ECM

On 9 January 2024, the Swiss Medicines Agency Swissmedic informed about critical deficits in the system of medical device regulation. 

To ensure safety and efficiency, medical devices and the quality management system of medical device manufacturers are inspected and continuously monitored by notified bodies. The German notified body ECM (ECM-Zertifizierungsgesellschaft für Medizinprodukte in

Europa GmbH, Aachen) used to be such a notified body until its designation expired on 25 May 2020 and has not been renewed by the corresponding German authority. Since then, ECM-certified products have no longer been monitored in accordance with the requirements of the Therapeutic Products Act.

Last year, Swissmedic discovered that ECM certified medical devices of foreign manufacturers were still being sold in Switzerland. In response, the Swiss authority informed the approximately 980 registered Swiss authorised representatives of foreign manufacturers about the problem in June 2023 and asked them to review their mandates.

During the period from July to October 2023, the Swiss authority then carried out extensive research for a sample check. This revealed that 7 of the 15 specifically selected authorised representatives had products with an ECM certificate in their portfolio.

Swissmedic has ordered the authorised representatives concerned to take corrective action to ensure that the products distributed in Switzerland comply with the regulatory requirements.


Source:

Swissmedic:  Announcements on market control issues

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
Previous
Next